Soleno Therapeutics Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Soleno Therapeutics for violations of securities laws, concerning securities transactions between March 26, 2025, and November 4, 2025, with a deadline for participation set for May 5, 2026.
- False Statement Allegations: The complaint alleges that Soleno misled the market regarding safety issues in its DCCR clinical trial, resulting in investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Concealed Safety Risks: Soleno's DCCR treatment exhibited greater safety risks than disclosed, along with lower commercial viability and increased adverse event risks, leading to direct financial losses for investors due to the lack of transparency.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before class certification to ensure their rights are protected and to seek compensation for their losses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
